Document is current
Any future updates will be listed below
-
Authors
Norris, Jordan E. https://orcid.org/0000-0002-4438-3416
Berry-Kravis, Elizabeth M.
Harnett, Mark D.
Reines, Scott A.
Smith, Melody R.
Auger, Emma K.
Outterson, Abigail H.
Furman, Jeremiah
Gurney, Mark E.
Ethridge, Lauren E. https://orcid.org/0000-0003-0601-6911
-
Funding
Funding for this research was provided by:
FRAXA Research Foundation
U.S. Department of Health & Human Services | National Institutes of Health (HD076189)
National Fragile X Foundation
University of Oklahoma (Research Publication Subvention Funding Program)
- License Information
-
More Information
Article History
Received: 16 March 2024
Revised: 21 July 2025
Accepted: 18 August 2025
First Online: 28 August 2025
Competing interests
: E.M.B.-K., M.R.S., E.K.A., A.O., C.M. and J.F. declare no competing interests. M.D.H. and S.A.R. are paid consultants to Tetra Therapeutics. M.E.G. is an employee of Tetra. Therapeutics, which is a wholly owned subsidiary of Shionogi & Company that has a financial interest in BPN14770. J.E.N, and L.E.E. received research funding from Shionogi & Company for independent data analysis; all funds are contracted to and managed by the University of Oklahoma.
